The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In recent years, a number of studies have shown that clinical drug trials financed by pharmaceutical companies yield favorable results for company products more often than independent trials do. Moreover, pharmaceutical companies have been found to influence drug trials in various ways. This paper provides an overview of the findings of current, systematic studies on this topic. METHODS: Publications retrieved from a systematic Medline search on this topic from 1 November 2002 to 16 December 2009 were independently evaluated and selected by two of the authors. These publications were supplemented by further ones found in their references sections. RESULTS: 57 publications were included for evaluation in Parts 1 and 2 of this article. Published drug trials that were financed by pharmaceutical companies, or whose authors declared a financial conflict of interest, were found to yield favorable results for the drug manufacturer more frequently than independently financed trials whose authors had no such conflicts. The results were also interpreted favorably more often than in independently financed trials. Furthermore, there was evidence that pharmaceutical companies influenced study protocols in a way that was favorable to themselves. The methodological quality of trials financed by pharmaceutical companies was not found to be any worse than that of trials financed in other ways. CONCLUSION: Published drug trials that are financed by pharmaceutical companies may present a distorted picture. This cannot be explained by any difference in methodological quality between such trials and trials financed in other ways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339 · cited 1×
“, uncertainty which of the alternative approaches benefits the patient most, forms the ethical foundation of clinical studies in which the probands receive various treatments (14).”
BackgroundPharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 4×
“showed that drug trials financed by pharmaceutical companies are less likely to be published, but that those published more frequently yield positive results for the sponsors’ products than do independently funded studies (8).”
BackgroundResultInfluentialScope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816 · cited 4×
“Methods Systematic literature review The criteria for the selection of systematic investigations into the effects of financing on study results were oriented on the above-mentioned reviews (7, 8).”
BackgroundResultInfluentialAls-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals
Flanagin, A. (1998) · JAMA · doi:10.1001/jama.280.3.222 · Cited by 553
Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1957 · Cited by 318
Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040184 · Cited by 249
Yank, V., Rennie, D., & Bero, L. A. (2007) · BMJ · doi:10.1136/bmj.39376.447211.be · Cited by 235
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
Peppercorn, J., Blood, E., Winer, E., & Partridge, A. (2007) · Cancer · doi:10.1002/cncr.22528 · Cited by 123
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Margulis, A. V., Pladevall, M., Riera-Guardia, N., Varas-Lorenzo, C., Hazell, L., Berkman, N., Viswanathan, M., & Perez-Gutthann, S. (2014) · Clinical Epidemiology · doi:10.2147/clep.s66677 · Cited by 441
Newer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
An analysis of the use of animal models in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200306 · Cited by 182
Industry sponsorship and research outcome: systematic review with meta-analysis
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5293-7 · Cited by 162
An analysis of the use of dogs in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2013) · Alternatives to Laboratory Animals · doi:10.1177/026119291304100504 · Cited by 71
Conflicts of interest and spin in reviews of psychological therapies: a systematic review
Lieb, K., Osten-Sacken, J. V. D., Stoffers-Winterling, J., Reiss, N., & Barth, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010606 · Cited by 69
Self-citationEpistemic Corruption, the Pharmaceutical Industry, and the Body of Medical Science
Sismondo, S. (2021) · Frontiers in Research Metrics and Analytics · doi:10.3389/frma.2021.614013 · Cited by 63
“In all of its dimensions, the 2017 meta-analysis arrives at the same or similar results as had earlier quantitative and qualitative reviews (Bekelman et al., 2003; Lexchin et al., 2003; Schott et al., 2010).”
ResultBaethge, C. (2013) · PeerJ · doi:10.7717/peerj.128 · Cited by 17
Saa, C., Bunout, D., & Hirsch, S. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001322 · Cited by 10
Metadata
- Authors
- Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W.-D., & Lieb, K.
- Venue
- Deutsches Ärzteblatt international
- Publisher
- Deutscher Arzte-Verlag GmbH
- Published
- 2010-04-23
- Volume
- 107
- Issue
- 16
- Pages
- 279-85
- ISSN
- 1866-0452 (ISSN-L)
- OpenAlex
- W1524740654
- Cited by
- 101
- References
- 9
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.